334 related articles for article (PubMed ID: 17948267)
1. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations.
Beveridge NE; Price DA; Casazza JP; Pathan AA; Sander CR; Asher TE; Ambrozak DR; Precopio ML; Scheinberg P; Alder NC; Roederer M; Koup RA; Douek DC; Hill AV; McShane H
Eur J Immunol; 2007 Nov; 37(11):3089-100. PubMed ID: 17948267
[TBL] [Abstract][Full Text] [Related]
2. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
[TBL] [Abstract][Full Text] [Related]
3. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
Goonetilleke NP; McShane H; Hannan CM; Anderson RJ; Brookes RH; Hill AV
J Immunol; 2003 Aug; 171(3):1602-9. PubMed ID: 12874255
[TBL] [Abstract][Full Text] [Related]
4. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells.
Scriba TJ; Tameris M; Mansoor N; Smit E; van der Merwe L; Isaacs F; Keyser A; Moyo S; Brittain N; Lawrie A; Gelderbloem S; Veldsman A; Hatherill M; Hawkridge A; Hill AV; Hussey GD; Mahomed H; McShane H; Hanekom WA
Eur J Immunol; 2010 Jan; 40(1):279-90. PubMed ID: 20017188
[TBL] [Abstract][Full Text] [Related]
5. Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
Manjaly Thomas ZR; Satti I; Marshall JL; Harris SA; Lopez Ramon R; Hamidi A; Minhinnick A; Riste M; Stockdale L; Lawrie AM; Vermaak S; Wilkie M; Bettinson H; McShane H
PLoS Med; 2019 Apr; 16(4):e1002790. PubMed ID: 31039172
[TBL] [Abstract][Full Text] [Related]
6. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.
Verreck FA; Vervenne RA; Kondova I; van Kralingen KW; Remarque EJ; Braskamp G; van der Werff NM; Kersbergen A; Ottenhoff TH; Heidt PJ; Gilbert SC; Gicquel B; Hill AV; Martin C; McShane H; Thomas AW
PLoS One; 2009; 4(4):e5264. PubMed ID: 19367339
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis.
Tchilian EZ; Desel C; Forbes EK; Bandermann S; Sander CR; Hill AV; McShane H; Kaufmann SH
Infect Immun; 2009 Feb; 77(2):622-31. PubMed ID: 19064635
[TBL] [Abstract][Full Text] [Related]
8. Heterologous vaccination against human tuberculosis modulates antigen-specific CD4+ T-cell function.
Dintwe OB; Day CL; Smit E; Nemes E; Gray C; Tameris M; McShane H; Mahomed H; Hanekom WA; Scriba TJ
Eur J Immunol; 2013 Sep; 43(9):2409-20. PubMed ID: 23737382
[TBL] [Abstract][Full Text] [Related]
9. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
Romano M; D'Souza S; Adnet PY; Laali R; Jurion F; Palfliet K; Huygen K
Vaccine; 2006 Apr; 24(16):3353-64. PubMed ID: 16488518
[TBL] [Abstract][Full Text] [Related]
10. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.
McShane H; Pathan AA; Sander CR; Keating SM; Gilbert SC; Huygen K; Fletcher HA; Hill AV
Nat Med; 2004 Nov; 10(11):1240-4. PubMed ID: 15502839
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.
Hawkridge T; Scriba TJ; Gelderbloem S; Smit E; Tameris M; Moyo S; Lang T; Veldsman A; Hatherill M; Merwe Lv; Fletcher HA; Mahomed H; Hill AV; Hanekom WA; Hussey GD; McShane H
J Infect Dis; 2008 Aug; 198(4):544-52. PubMed ID: 18582195
[TBL] [Abstract][Full Text] [Related]
12. Protection associated with a TB vaccine is linked to increased frequency of Ag85A-specific CD4(+) T cells but no increase in avidity for Ag85A.
Metcalfe HJ; Steinbach S; Jones GJ; Connelley T; Morrison WI; Vordermeier M; Villarreal-Ramos B
Vaccine; 2016 Aug; 34(38):4520-4525. PubMed ID: 27498622
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
Whelan KT; Pathan AA; Sander CR; Fletcher HA; Poulton I; Alder NC; Hill AV; McShane H
PLoS One; 2009 Jun; 4(6):e5934. PubMed ID: 19529780
[TBL] [Abstract][Full Text] [Related]
14. Process of assay selection and optimization for the study of case and control samples from a phase IIb efficacy trial of a candidate tuberculosis vaccine, MVA85A.
Harris SA; Satti I; Matsumiya M; Stockdale L; Chomka A; Tanner R; O'Shea MK; Manjaly Thomas ZR; Tameris M; Mahomed H; Scriba TJ; Hanekom WA; Fletcher HA; McShane H
Clin Vaccine Immunol; 2014 Jul; 21(7):1005-11. PubMed ID: 24828094
[TBL] [Abstract][Full Text] [Related]
15. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.
Scriba TJ; Tameris M; Mansoor N; Smit E; van der Merwe L; Mauff K; Hughes EJ; Moyo S; Brittain N; Lawrie A; Mulenga H; de Kock M; Gelderbloem S; Veldsman A; Hatherill M; Geldenhuys H; Hill AV; Hussey GD; Mahomed H; Hanekom WA; McShane H
J Infect Dis; 2011 Jun; 203(12):1832-43. PubMed ID: 21606542
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.
Wilkie M; Satti I; Minhinnick A; Harris S; Riste M; Ramon RL; Sheehan S; Thomas ZM; Wright D; Stockdale L; Hamidi A; O'Shea MK; Dwivedi K; Behrens HM; Davenne T; Morton J; Vermaak S; Lawrie A; Moss P; McShane H
Vaccine; 2020 Jan; 38(4):779-789. PubMed ID: 31735500
[TBL] [Abstract][Full Text] [Related]
17. The Profile of T Cell Responses in Bacille Calmette-Guérin-Primed Mice Boosted by a Novel Sendai Virus Vectored Anti-Tuberculosis Vaccine.
Hu Z; Gu L; Li CL; Shu T; Lowrie DB; Fan XY
Front Immunol; 2018; 9():1796. PubMed ID: 30123219
[TBL] [Abstract][Full Text] [Related]
18. Functional, Antigen-Specific Stem Cell Memory (T
Mpande CAM; Dintwe OB; Musvosvi M; Mabwe S; Bilek N; Hatherill M; Nemes E; Scriba TJ;
Front Immunol; 2018; 9():324. PubMed ID: 29545791
[TBL] [Abstract][Full Text] [Related]
19. Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.
Fletcher HA; Pathan AA; Berthoud TK; Dunachie SJ; Whelan KT; Alder NC; Sander CR; Hill AV; McShane H
Vaccine; 2008 Sep; 26(41):5269-75. PubMed ID: 18682270
[TBL] [Abstract][Full Text] [Related]
20. Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection.
Zhang M; Dong C; Xiong S
Hum Vaccin Immunother; 2017 Apr; 13(4):816-822. PubMed ID: 27960596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
